
Stephen Stahl
American psychiatrist
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Jul 29, 2026
E287 - Deprescribing Practices in Psychiatry with Drs. Stephen Stahl and Jeffrey Strawn
11:36
11:52
11:59
12:07
12:14
47:46

Stephen StahlGUEST
Well, um, I, I think that we don't know when somebody is responding, whether that needs to go forever.

Stephen StahlGUEST
You know, registration trials tend to be, you know, a few weeks to a few months, sometimes a year.

Stephen StahlGUEST
But, you know, being able to show that sustained remission is due to the presence of the drug is, is not well established.

Stephen StahlGUEST
And so the question is, have the receptors done whatever they need to do to sustain- They're, uh, they're, uh, they're good parts.

Stephen StahlGUEST
I mean, probably receptor adaptations occur for the good parts of why the medicines do work, and then of course, there's the off-target things, um, uh, and, and it-- which actually you don't want, but are part and parcel of the drug's action.
35 MINS LATER

Andrew CutlerHOST
What about sedative hypnotics? You know, let's say the Z drugs or even, uh, etrazodone or something like that.